Related references
Note: Only part of the references are listed.Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy Secondary Analysis From the FOURIER Randomized Clinical Trial
Prakash Deedwania et al.
JAMA CARDIOLOGY (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
Inclisiran: First Approval
Yvette N. Lamb
DRUGS (2021)
Proprotein Convertase Subtilisin/Kexin Type 9 A View beyond the Canonical Cholesterol-Lowering Impact
Chiara Macchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Kiran Musunuru et al.
NATURE (2021)
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Tanja Rothgangl et al.
NATURE BIOTECHNOLOGY (2021)
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk
Arturo Cesaro et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Blood flow patterns regulate PCSK9 secretion viaMyD88-mediated pro-inflammatory cytokines
Shijie Liu et al.
CARDIOVASCULAR RESEARCH (2020)
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial
Nicholas A. Marston et al.
CIRCULATION (2020)
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Amy Damask et al.
CIRCULATION (2020)
Influence of Cardiometabolic Risk Factors on Platelet Function
Cristina Barale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab (R): A prospective cohort study
Matteo Nicola D. Di Minno et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Robert P. Giugliano et al.
STROKE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
Vittoria Cammisotto et al.
ANTIOXIDANTS (2020)
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design
Jacopo Sgrignani et al.
CHEMMEDCHEM (2020)
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy
Alessandro Di Minno et al.
THROMBOSIS RESEARCH (2020)
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Hyun-Duk Jang et al.
EUROPEAN HEART JOURNAL (2020)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Donna K. Arnett et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors
A. F. G. Cicero et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
Manuela Casula et al.
PHARMACOLOGICAL RESEARCH (2019)
Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin
Cristina Barale et al.
THROMBOSIS RESEARCH (2019)
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
I. K. Luirink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Platelet biology and functions: new concepts and clinical perspectives
Paola E. J. van der Meijden et al.
NATURE REVIEWS CARDIOLOGY (2019)
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Nelson Wang et al.
Lancet Diabetes & Endocrinology (2019)
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience
Felice Gragnano et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2018)
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
Hua Sun et al.
JOURNAL OF LIPID RESEARCH (2018)
Lipid management in ACS: Should we go lower faster?
Baris Gencer et al.
ATHEROSCLEROSIS (2018)
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2018)
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Alena Grebe et al.
CIRCULATION RESEARCH (2018)
Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis
Milka Koupenova et al.
CIRCULATION RESEARCH (2018)
Inclisiran for the treatment of dyslipidemia
Toshiyuki Nishikido et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report
M. G. Zenti et al.
JOURNAL OF CLINICAL APHERESIS (2018)
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
Merel L. Hartgers et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Improved endothelial function after short-term therapy with evolocumab
Guglielmo Maulucci et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
Significance of urinary 11-dehydro-thromboxane B-2 in age-related diseases: Focus on atherothrombosis
Paola Simeone et al.
AGEING RESEARCH REVIEWS (2018)
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Paolo Raggi et al.
ATHEROSCLEROSIS (2018)
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
Suzanne Schol-Gelok et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Safety and efficacy of statin therapy
Bhavin B. Adhyaru et al.
NATURE REVIEWS CARDIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Constantine E. Kosmas et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia
Cristina Barale et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
PCSK9 and Atherosclerosis - Lipids and Beyond
Michael D. Shapiro et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
G. Kees Hovingh et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation
Sandeep Kumar et al.
LABORATORY INVESTIGATION (2017)
Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
Jiao Li et al.
MOLECULAR MEDICINE REPORTS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
Hui Wang et al.
SCIENTIFIC REPORTS (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study
B. Cariou et al.
DIABETES & METABOLISM (2017)
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
Bertrand Cariou et al.
ATHEROSCLEROSIS (2016)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Hagai Tavori et al.
CARDIOVASCULAR RESEARCH (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
Hayato Tada et al.
CIRCULATION JOURNAL (2016)
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
Wuxiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
DIFFERENTIAL EXPRESSION OF PCSK9 MODULATES INFECTION, INFLAMMATION, AND COAGULATION IN A MURINE MODEL OF SEPSIS
Dhruva J. Dwivedi et al.
SHOCK (2016)
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
Steve Poirier et al.
PLOS ONE (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis
Travis J. Gould et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
A systematic literature review of the effect of carotid atherosclerosis on local vessel stiffness and elasticity
Mari E. Boesen et al.
ATHEROSCLEROSIS (2015)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
PCSK9: A key factor modulating atherosclerosis
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells
Paula Costales et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Ezetimibe plus a Statin after Acute Coronary Syndromes
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison of the Proinflammatory and Procoagulant Properties of Nuclear, Mitochondrial, and Bacterial DNA
Vinai C. Bhagirath et al.
SHOCK (2015)
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
Steve Poirier et al.
CELL REPORTS (2015)
Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages
Ekhtear Hossain et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia A Cross-Sectional Cohort Study
Yascara Grisel Luna Saavedra et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms
Travis J. Gould et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis
Meaghan D. Waltmann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
Mechanisms of Plaque Formation and Rupture
Jacob Fog Bentzon et al.
CIRCULATION RESEARCH (2014)
Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering
Martin Maeng Bjorklund et al.
CIRCULATION RESEARCH (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
PCSK9 gene mutations and low-density lipoprotein cholesterol
Na-Qiong Wu et al.
CLINICA CHIMICA ACTA (2014)
Pathophysiology of Acute Coronary Syndrome
Carlos G. Santos-Gallego et al.
CURRENT ATHEROSCLEROSIS REPORTS (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Keith R. Walley et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis
Eliano P. Navarese et al.
ANNALS OF INTERNAL MEDICINE (2013)
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
Emile Levy et al.
ATHEROSCLEROSIS (2013)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Hagai Tavori et al.
CIRCULATION (2013)
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Tanja Kosenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Neutrophil Extracellular Trap (NET) Impact on Deep Vein ThrombosisTobias
Tobias A. Fuchs et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Michael T. Lipari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
Marie-Luise von Bruehl et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Deletion of the High-Density Lipoprotein Receptor Scavenger Receptor BI in Mice Modulates Thrombosis Susceptibility and Indirectly Affects Platelet Function by Elevation of Plasma Free Cholesterol
Suzanne J. A. Korporaal et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Clinical aspects of PCSK9
Bertrand Cariou et al.
ATHEROSCLEROSIS (2011)
Identification of proprotein convertase substrates using genome-wide expression correlation analysis
Hannu Turpeinen et al.
BMC GENOMICS (2011)
Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells
Seyed A. Mousavi et al.
FEBS JOURNAL (2011)
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus
L. L. Swystun et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy
James E. McLaren et al.
PROGRESS IN LIPID RESEARCH (2011)
A Key Enzyme in the Biogenesis of Lysosomes Is a Protease That Regulates Cholesterol Metabolism
Katrin Marschner et al.
SCIENCE (2011)
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling
Hsiu-Chung Ou et al.
JOURNAL OF APPLIED PHYSIOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell et al.
NATURE (2010)
MEROPS: the peptidase database
Neil D. Rawlings et al.
NUCLEIC ACIDS RESEARCH (2010)
In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin
Isabella Russo et al.
OBESITY (2010)
Extracellular DNA traps promote thrombosis
Tobias A. Fuchs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Subtilases: The superfamily of subtilisin-like serine proteases
Roland J. Siezen et al.
PROTEIN SCIENCE (2010)
Commentary PCSK9 variants: A new database
Sarah E. A. Leigha et al.
ATHEROSCLEROSIS (2009)
Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
Jamie Cameron et al.
ATHEROSCLEROSIS (2009)
Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes
Sanae Kourimate et al.
ATHEROSCLEROSIS (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
S. A. Mousavi et al.
JOURNAL OF INTERNAL MEDICINE (2009)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Platelet count and the risk for thrombosis and death in the elderly
J. G. van der Bom et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Extracellular histones are major mediators of death in sepsis
Jun Xu et al.
NATURE MEDICINE (2009)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Neutrophil-derived circulating free DNA (cf-DNA/NETs):: A potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis
Stefan Margraf et al.
SHOCK (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Eugene A. Podrez et al.
NATURE MEDICINE (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The proprotein convertases are potential targets in the treatment of dyslipidemia
Nabil G. Seidah et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling - Molecular, cellular, and vascular behavior
Yiannis S. Chatzizisis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice
L. Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Platelet nitric oxide responsiveness - A novel prognostic marker in acute coronary syndromes
SR Willoughby et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate
CA Graham et al.
ATHEROSCLEROSIS (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
Neutrophil extracellular traps kill bacteria
V Brinkmann et al.
SCIENCE (2004)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells
V Llorente-Cortés et al.
CIRCULATION (2004)
Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels
R Riba et al.
ATHEROSCLEROSIS (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Low-density lipoprotein and its effect on human blood platelets
IAM Relou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Elevated cell-free serum DNA detected in patients with myocardial infarction
CPY Chang et al.
CLINICA CHIMICA ACTA (2003)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - The MIRACL study: A randomized controlled trial
GG Schwartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
